NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 03 02:21PM ET
4.30
Dollar change
+0.04
Percentage change
0.94
%
IndexRUT P/E- EPS (ttm)-0.63 Insider Own24.88% Shs Outstand45.25M Perf Week-10.42%
Market Cap194.77M Forward P/E- EPS next Y-1.06 Insider Trans-0.13% Shs Float34.02M Perf Month-11.70%
Enterprise Value135.06M PEG- EPS next Q-0.26 Inst Own59.03% Short Float7.80% Perf Quarter-10.42%
Income-28.23M P/S2.20 EPS this Y-47.16% Inst Trans-0.27% Short Ratio11.57 Perf Half Y-44.59%
Sales88.66M P/B2.18 EPS next Y-7.10% ROA-23.93% Short Interest2.65M Perf YTD-45.08%
Book/sh1.98 P/C3.23 EPS next 5Y-17.97% ROE-29.93% 52W High16.11 -73.31% Perf Year-63.65%
Cash/sh1.33 P/FCF- EPS past 3/5Y19.44% 21.90% ROIC-31.51% 52W Low3.55 21.13% Perf 3Y-70.34%
Dividend Est.- EV/EBITDA- Sales past 3/5Y35.95% - Gross Margin82.06% Volatility5.24% 7.71% Perf 5Y-90.55%
Dividend TTM- EV/Sales1.52 EPS Y/Y TTM-27.70% Oper. Margin-34.78% ATR (14)0.34 Perf 10Y-
Dividend Ex-Date- Quick Ratio4.35 Sales Y/Y TTM4.92% Profit Margin-31.84% RSI (14)42.54 Recom1.58
Dividend Gr. 3/5Y- - Current Ratio4.77 EPS Q/Q23.91% SMA20-9.81% Beta0.57 Target Price14.58
Payout- Debt/Eq0.01 Sales Q/Q4.88% SMA50-3.39% Rel Volume0.35 Prev Close4.26
Employees107 LT Debt/Eq0.00 EarningsMay 13 BMO SMA200-45.08% Avg Volume229.25K Price4.30
IPOSep 21, 2018 Option/ShortYes / Yes EPS/Sales Surpr.43.45% 6.69% Trades Volume81,293 Change0.94%
Date Action Analyst Rating Change Price Target Change
Apr-22-25Downgrade BofA Securities Neutral → Underperform $3
Nov-18-24Initiated Oppenheimer Outperform $23
Aug-16-24Initiated Cantor Fitzgerald Overweight $20
Jun-28-24Initiated Truist Buy $21
May-10-23Upgrade Wedbush Neutral → Outperform $5 → $13
Apr-03-23Downgrade Guggenheim Buy → Neutral
Jan-27-23Downgrade Morgan Stanley Equal-Weight → Underweight $4
Jan-05-23Downgrade Cowen Outperform → Market Perform
Dec-02-22Downgrade BofA Securities Buy → Neutral $23 → $5
Dec-02-22Downgrade BofA Securities Buy → Neutral
May-28-25 06:35AM
May-26-25 10:57PM
10:00AM
May-14-25 09:18AM
03:05AM
10:29PM Loading…
May-13-25 10:29PM
07:45AM
07:05AM
06:35AM
May-12-25 09:43AM
08:15AM
May-09-25 08:35AM
May-07-25 06:15PM
09:06AM
07:05AM
07:05AM Loading…
May-06-25 07:05AM
Apr-30-25 10:01AM
Apr-29-25 10:01AM
Apr-27-25 03:00PM
Apr-25-25 07:35AM
Apr-11-25 04:35PM
Mar-05-25 02:04AM
01:34AM
Mar-04-25 07:50AM
07:45AM
06:35AM
Mar-03-25 07:30AM
07:21AM
Feb-25-25 10:00AM
Feb-20-25 04:05PM
07:30AM Loading…
Feb-06-25 07:30AM
Feb-04-25 09:35AM
Feb-03-25 09:35AM
Jan-31-25 07:35AM
Jan-11-25 09:49AM
Jan-10-25 09:26AM
09:26AM
07:35AM
07:05AM
Jan-08-25 07:25AM
Dec-23-24 07:30AM
Dec-15-24 06:04AM
Dec-07-24 12:00PM
Nov-27-24 07:35AM
Nov-09-24 06:01AM
Nov-08-24 07:45AM
06:35AM
Nov-07-24 07:08AM
Nov-04-24 07:35AM
Nov-01-24 10:00AM
Oct-25-24 07:05AM
Oct-09-24 06:12PM
Oct-01-24 07:05AM
Sep-06-24 07:30AM
Sep-03-24 08:32AM
Aug-12-24 06:33PM
07:40AM
06:30AM
Aug-09-24 07:20AM
Aug-07-24 07:05AM
Aug-05-24 04:05PM
Jul-01-24 04:05PM
Jun-07-24 07:05AM
Jun-05-24 07:05AM
Jun-01-24 08:15AM
08:05AM
May-09-24 11:58AM
03:04AM
May-08-24 09:57PM
May-07-24 09:55PM
06:12PM
05:55PM
04:05PM
Apr-26-24 07:05AM
Apr-25-24 04:05PM
Mar-28-24 09:55AM
Mar-20-24 07:37AM
Mar-14-24 09:05AM
Mar-12-24 09:55AM
Mar-05-24 12:00PM
Mar-04-24 08:45AM
07:30AM
Mar-01-24 09:42PM
Feb-29-24 05:25PM
04:37PM
04:05PM
Feb-22-24 10:00AM
Feb-16-24 07:30AM
Feb-13-24 04:10AM
Jan-02-24 04:05PM
Dec-13-23 04:05PM
Dec-12-23 01:05AM
Dec-03-23 03:04AM
Nov-30-23 11:04PM
Nov-15-23 01:14PM
01:33AM
Nov-13-23 05:31PM
05:25PM
04:05PM
Nov-08-23 12:00PM
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in Princeton, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gad ThomasCHIEF BUSINESS OFFICERJun 03 '25Option Exercise2.00103,000206,000305,721Jun 05 07:17 PM
Rossi Michael JPRESIDENT & CEOMar 07 '25Sale5.203,91720,368137,083Mar 11 08:17 PM
Gad ThomasCHIEF BUSINESS OFFICERMar 07 '25Sale5.2310,81056,536202,721Mar 11 08:15 PM
Rajah VigneshOfficerMar 07 '25Proposed Sale5.204,94625,743Mar 07 04:40 PM
Smith Susan LauraOfficerMar 07 '25Proposed Sale5.265,52829,100Mar 07 04:36 PM
Gad ThomasOfficerMar 07 '25Proposed Sale5.2310,81056,547Mar 07 04:32 PM
Rossi Michael JOfficerMar 07 '25Proposed Sale5.203,91720,388Mar 07 04:26 PM
Gad ThomasCHIEF BUSINESS OFFICERSep 19 '24Option Exercise4.3822,831100,000181,531Sep 20 04:15 PM
Gad ThomasCHIEF BUSINESS OFFICERSep 13 '24Sale13.4765,000875,55097,681Sep 17 08:05 PM
Gad ThomasCHIEF BUSINESS OFFICERSep 16 '24Sale12.9730,000389,10067,681Sep 17 08:05 PM
Thomas GadOfficerSep 13 '24Proposed Sale13.74100,0001,374,000Sep 13 04:19 PM
Ber GerardDirectorSep 03 '24Proposed Sale13.8313,950192,928Sep 03 05:00 PM
Lund-Hansen TorbenSVP & CHIEF TECHNICAL OFFICERAug 28 '24Option Exercise4.3850,000219,00085,600Aug 30 04:15 PM
Lund-Hansen TorbenSVP & CHIEF TECHNICAL OFFICERAug 28 '24Sale15.3750,000768,50035,600Aug 30 04:15 PM
Lund-Hansen TorbenOfficerAug 28 '24Proposed Sale15.3750,000768,432Aug 28 05:12 PM
Wilms JorisSVP & CHIEF OPERATING OFFICERAug 26 '24Sale14.695,00073,45030,600Aug 27 05:05 PM
Wilms JorisOfficerAug 26 '24Proposed Sale14.695,00073,450Aug 26 04:12 PM